|
|
Volumn 101, Issue 19, 2009, Pages 1300-1301
|
|
Epigenetic therapies move into new territory, but how exactly do they work?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
5 AZA 2' DEOXYCYTIDINE;
ANTINEOPLASTIC AGENT;
ANTINEOPLASTIC ANTIMETABOLITE;
AZACITIDINE;
DNA BINDING PROTEIN;
DNA METHYLTRANSFERASE;
DRUG DERIVATIVE;
ENZYME INHIBITOR;
EZH2 PROTEIN, HUMAN;
HISTONE DEACETYLASE INHIBITOR;
TRANSCRIPTION FACTOR;
ANIMAL;
DNA METHYLATION;
DRUG ANTAGONISM;
DRUG EFFECT;
DRUG POTENTIATION;
ENZYMOLOGY;
GENETIC EPIGENESIS;
GENETICS;
HUMAN;
MYELODYSPLASTIC SYNDROME;
NOTE;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
SURVIVAL;
XENOGRAFT;
ANIMALS;
ANTIMETABOLITES, ANTINEOPLASTIC;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
AZACITIDINE;
DNA METHYLATION;
DNA MODIFICATION METHYLASES;
DNA-BINDING PROTEINS;
DRUG SYNERGISM;
ENZYME INHIBITORS;
EPIGENESIS, GENETIC;
HISTONE DEACETYLASE INHIBITORS;
HUMANS;
MYELODYSPLASTIC SYNDROMES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
SURVIVAL ANALYSIS;
TRANSCRIPTION FACTORS;
TRANSPLANTATION, HETEROLOGOUS;
|
|
EID: 77954672845
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djp342 Document Type: Note |
|
Times cited : (12)
|
|
References (0)
|
